Stock analysts at StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Free Report) in a research note issued on Tuesday. The brokerage set a “sell” rating on the stock.
Navidea Biopharmaceuticals Price Performance
NYSE:NAVB opened at $0.00 on Tuesday. The stock’s 50 day moving average price is $0.03 and its two-hundred day moving average price is $0.04. The firm has a market capitalization of $50,042.00, a price-to-earnings ratio of -0.01 and a beta of 0.75. Navidea Biopharmaceuticals has a 12-month low of $0.00 and a 12-month high of $0.15.
Navidea Biopharmaceuticals Company Profile
Read More
- Five stocks we like better than Navidea Biopharmaceuticals
- 3 Healthcare Dividend Stocks to Buy
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- Find and Profitably Trade Stocks at 52-Week Lows
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- Technology Stocks Explained: Here’s What to Know About Tech
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.